Daxor Awarded $550K U.S. Defense Health Agency Contract For Added Capabilities To Its Point-Of-Care Blood Volume Analyzer
Portfolio Pulse from Benzinga Newsdesk
Daxor Corporation (NASDAQ:DXR) has been awarded a $550K contract extension from the U.S. Defense Health Agency to enhance its blood volume analyzer with hematocrit measurement capabilities, eliminating the need for third-party devices.
July 24, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daxor Corporation has received a $550K contract extension from the U.S. Defense Health Agency to add hematocrit measurement to its blood volume analyzer, potentially increasing its market appeal and revenue.
The contract extension from the U.S. Defense Health Agency signifies strong governmental support and funding for Daxor's technology. The integration of hematocrit measurement into the blood volume analyzer could make the product more comprehensive and attractive to healthcare providers, potentially boosting sales and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100